United States to buy and donate 500 million COVID-19 vaccine doses to the world; an FDA advisor resigns over a controversial Alzheimer drug approval; Nevada becomes the second state to offer state-managed health insurance plans.
President Biden is set to announce his administration will purchase 500 million doses of Pfizer’s COVID-19 vaccine to be donated to the rest of the world, The Washington Post reports. The first 200 million will be distributed via COVAX in 2021 and the rest will be shared in the first half of 2022. The vaccines will be targeted at low- and middle-income countries, while Pfizer is selling the shots to the United States at a low “not-for-profit” price. The deal was lauded by public health experts as many have been pushing for increased efforts to vaccinate the world. According to The Hill, the United States is also in talks with Moderna to buy more vaccines to send abroad.
A member of the FDA’s advisory committee, David Knopman, MD, has resigned over the agency’s approval of a new Alzheimer’s drug, Biogen’s aducanumab (Aduhelm), CNN reports. Although the drug marks the first new therapy approval in the space since 2003, the decision proved controversial as the FDA’s Peripheral and Central Nervous System Drugs Advisory Committee raised objections to doing so. Advisors said there was not enough data to support the drug’s approval as initial trials indicated it did not improve the condition at all. In November, the committee voted against the suggestion the drug could help patients.
Nevada is slated to become the second state in the nation to offer state-managed health insurance plans, according to The Associated Press. Washington is currently the only state with a similar law in place. The law, signed by Nevada Governor Steve Sisolak, seeks to create the health insurance plans by 2026 and was passed by the state’s legislature in May. It will require insurers bid to cover Medicaid recipients, while state employees would also bid to offer a public-option plan. Those supporting the measure argue it will expand coverage to Nevada’s 350,000 uninsured residents, while opponents worry forcing hospitals and providers to accept patients at lower costs may make them move out of state.
The Impact of Cost Sharing on High-Value Care
March 14th 2025Michael Chernew, PhD, professor of health care policy and director of the Healthcare Markets and Regulation Lab, Harvard Medical School, shares how cost-sharing policies shape access to critical health care services and influence value-based insurance design.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
PAH Treatment Benefits Extend to Patients With Repaired Congenital Heart Disease
March 14th 2025Historical data show the prevalence of pulmonary arterial hypertension (PAH) in adult patients with congenital heart disease ranges from 4% to 28%, according to studies from the US and Europe—and that the prevalence of these comorbid condition is on the rise.
Read More
Regenerating Neurons, Muscle, and Hope in the Field of Muscular Dystrophy
March 13th 2025The 2025 Muscular Dystrophy Association Clinical & Scientific Conference, convening in Dallas, Texas, from March 16-18, will feature clinical updates, expert insights, and breaking trial findings that sum up to a new frontier of care for neuromuscular diseases.
Read More